What are the indications for Carafate (sucralfate)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Carafate (Sucralfate) Indications

Carafate is FDA-approved for the short-term treatment (up to 8 weeks) of active duodenal ulcer. 1

FDA-Approved Indication

The only official FDA-approved indication for Carafate (sucralfate) suspension is:

  • Active duodenal ulcer - short-term treatment for up to 8 weeks 1

This remains the sole indication for which the medication has regulatory approval, despite decades of clinical use in other conditions.

Off-Label Uses in Critical Care

While not FDA-approved for stress ulcer prophylaxis (SUP), sucralfate has been studied extensively in critically ill patients. However, current evidence does not favor sucralfate as a first-line agent for SUP 2:

  • Sucralfate showed reduced pneumonia rates compared to PPIs (RR 0.49) and H2RAs (RR 0.83) 2
  • However, many studies used outdated gastric pH targets (>3.5) that are no longer standard practice 2
  • No evidence supports combining sucralfate with acid suppressants for SUP 2
  • When used for SUP, the recommended dose is ≤4g daily 2

Important caveat: PPIs and H2RAs are generally preferred over sucralfate for stress ulcer prophylaxis in modern critical care practice, as they more effectively reduce clinically important upper GI bleeding 2.

Other Off-Label Applications

Research suggests potential benefits in various mucocutaneous conditions, though none are FDA-approved 3:

Topical sucralfate has shown clinical benefit in:

  • Post-radiotherapy mucosal reactions 3, 4
  • Radiation-induced proctosigmoiditis 5
  • Recurrent aphthous stomatitis (71.4% improvement in one study) 6
  • Postoperative oral surgical wounds (significant pain reduction on days 3 and 7) 7
  • Diaper dermatitis and keratoconjunctivitis sicca 3

Oral/systemic uses studied (not FDA-approved):

  • Gastroesophageal reflux disease 5
  • Gastritis and dyspepsia 5
  • Stress ulcer prevention 2

Clinical Considerations

Contraindication: Known hypersensitivity to sucralfate or any excipients 1

Mechanism: Sucralfate works through multiple pathways including pepsin/bile acid adsorption, stimulation of bicarbonate and mucus secretion, prostaglandin synthesis, and mucosal protection 8. It forms a physical barrier over damaged epithelium 5.

Important limitation: Recent analysis questions the clinical value of sucralfate given the availability of more effective acid-suppressing medications, noting its continued high prescription rates despite limited evidence base 9.

Bottom line for prescribing: Stick to the FDA-approved indication of active duodenal ulcer unless using topically for mucocutaneous conditions where evidence supports benefit and other options have failed. For stress ulcer prophylaxis in ICU patients, prefer PPIs or H2RAs over sucralfate 2.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.